Biohaven announced that Nurtec™ ODT (rimegepant) is now available for the acute treatment of migraine with or without aura in adults.
Nurtec ODT is a calcitonin gene-related peptide receptor antagonist administered as an orally disintegrating tablet (ODT). The ODT can be placed on or under the tongue and disintegrates in saliva so that it can be swallowed without additional liquid. The tablet should be taken immediately after opening the blister pack and should not be stored outside of the blister pack for future use.
The approval of Nurtec ODT was based on efficacy data from a randomized, double-blind, placebo-controlled phase 3 trial that compared Nurtec ODT with placebo in 1466 adult patients for the acute treatment of migraine with and without aura. Results showed that a statistically significantly greater proportion of patients treated with Nurtec ODT achieved headache pain freedom and most bothersome symptom freedom 2 hours after a single dose, compared with placebo.
Based on data from a long-term, open-label phase 2/3 trial, the most common adverse reaction reported with Nurtec ODT use was nausea. The safety of treating more than 15 migraines in a 30-day period has not been established. Nurtec ODT should be avoided in patients with severe hepatic impairment as plasma concentrations of rimegepant were found to be significantly higher in these patients.
To increase affordability for patients, Biohaven has launched a patient savings program for eligible commercially insured patients; the copay savings card information can be found here.
“We are committed to helping ensure people with migraine have access to the treatments they need and therefore have established a comprehensive, best-in-class suite of patient affordability and access programs, including a patient starter kit and a co-pay savings card which will allow patients with commercial insurance to pay as little as $0 for Nurtec ODT,” said BJ Jones, Chief Commercial Officer of Migraine and Common Diseases at Biohaven.
For more information visit nurtec.com.
This article originally appeared on MPR